FDA places partial clinical hold on Neurocrine's NBI-77860

Neurocrine BioSciences Inc. (NASDAQ:NBIX) fell $2.27 to $43.01 in after-hours trading on Monday after it said FDA placed a partial clinical hold on NBI-77860, its candidate to treat congenital adrenal hyperplasia (CAH).

The company has suspended two planned clinical studies of the selective non-peptide corticotropin-releasing factor (CRF) receptor antagonist. No patients were enrolled in either study. ...